Effectiveness of palivizumab immunoprophylaxis to prevent respiratory syncytial virus hospitalizations in healthy full-term <6-month-old infants from the circumpolar region of Nunavik, Quebec, Canada

Effectiveness of palivizumab immunoprophylaxis to prevent respiratory syncytial virus hospitalizations in healthy full-term <6-month-old infants from the circumpolar region of Nunavik, Quebec, Canada

In Quebec, Canada, eligibility for palivizumab (PVZ) immunoprophylaxis was expanded in fall 2016 to include healthy-full-term (HFT) infants residing in the circumpolar region of Nunavik and aged <3 months at the start of the RSV season or born during the season. This study assessed the effectiven...

Full description

Bibliographic Details
Main Authors: Rodica Gilca, Marie-Noëlle Billard, Joseline Zafack, Jesse Papenburg, François D. Boucher, Hugues Charest, Marie Rochette, Gaston De Serres
Format: Article
Language:English
Published: Elsevier 2020-12-01
Series:Preventive Medicine Reports
Subjects:
Palivizumab
Healthy full-term infants
Respiratory syncytial virus
Respiratory hospitalization
Circumpolar region
Online Access:http://www.sciencedirect.com/science/article/pii/S221133552030139X

Internet

http://www.sciencedirect.com/science/article/pii/S221133552030139X

Similar Items